A Netherlands-based holding company, QIAGEN makes a significant expansion of its business in the Middle East region – Muscat, Oman, and Riyadh, Saudi Arabia and the region covering Venlo, the Netherlands. The expansion consists of three major developments – (1) In early 2024, QIAGEN aims to strengthen its commercial footprint in Riyadh, Saudi Arabia by opening its regional headquarters. (2) It has entered a memorandum of understanding (MoU) with the Ministry of Health of Saudi Arabia to address various public health issues . (3) QIAGEN has secured a tender from the Ministry of Health of the Sultanate of Oman, through its Commercial Partner Taiba Medserv LLC, to provide QuantiFERON-TB Gold Plus tests worldwide.
QIAGEN’s expansion in Riyadh, Saudi Arabia will accommodate its presence to strengthen the commitment in the Middle East. The signed MoU signifies –
- QIAGEN Digital Insights (QDI) is establishing a localized data center within the country to advance bioinformatics to ensure data protection and robust service while complying with national legislation.
- As per the guidelines of the World Health Organization (WHO) program, utilizing QIAGEN’s syndromic testing platform, QIAstat-Dx, can help assist the Ministry in eliminating meningitis. Under the WHO elimination initiative, assisting in executing a screening program aimed at preventing cervical cancer provides the nation with HPV tests.
- QuantiFERON-TB Gold Plus is used to create a national latent TB screening program.
Senior Director, Head of Sales and Marketing EEMEA at QIAGEN, Simona Grandits states, “At QIAGEN, we believe that improving healthcare outcomes starts with a strong foundation of collaboration and innovation, and we are excited to play a crucial role in advancing health and well-being throughout the Middle East. We are proud to contribute to the global efforts to end TB and other serious health threats. Our new regional headquarters in Riyadh will enable us to better serve our customers and foster strong partnerships with local stakeholders.”
Oman tuberculosis screening initiative
QIAGEN, through its Commercial Partner Taiba Medserv LLC, will supply hundreds of thousands of QuantiFERON-TB Gold Plus to provide tests for latent tuberculosis (TB) in the Gulf state. QuantiFERON-TB Gold Plus assay precisely detects TB infection by T-cells that releases interferon-gamma in response to TB-specific antigens. The Ministry of Health aims to test around 800,000 individuals within a two-year span and intends to provide direct medical care to individuals carrying TB bacteria without symptoms. The CDC and WHO endorse the implementation of QuantiFERON-TB Gold Plus in all environments to combat the global TB epidemic.